UPB
Upstream Bio Inc (UPB)
Healthcare • NASDAQ • $9.09+1.17%
- Symbol
- UPB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $9.09
- Daily Change
- +1.17%
- Market Cap
- $494.68M
- Trailing P/E
- N/A
- Forward P/E
- -2.82
- 52W High
- $33.68
- 52W Low
- $7.25
- Analyst Target
- $43.57
- Dividend Yield
- N/A
- Beta
- N/A
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Company websiteResearch UPB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.